YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in Q3– TransCon CNP ...

Shoppers aren’t imagining it: Luxury goods cost a lot more these days, with no improvement in quality to make up for it. Weak ...

The start-up rebranded itself as Hyntelo, complete with new name and logo. The name Hyntelo is ... leading pharmaceutical companies such as MSD, Novo Nordisk, Grünenthal and Takeda rely on ...

In a report released today, James Quigley from Goldman Sachs maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

With nearly $14 billion sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth ...

Novo Nordisk (NVO) reportedly plans to phase out production of its human insulin pens while it ramps up production of other ...